HS-20094
Phase 3Small molecule
Jiangsu Hansoh Pharmaceutical Co., Ltd.HS-20094 is one of 50 small molecule programs targeting Overweight. It is currently in Phase 3.
2
Indications
8
Total Trials
4
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
54 competitors in Overweight
#DrugCompanyPhaseTrials
1Ozempic
Novo NordiskApproved
Mounjaro
Eli LillyApproved
Glucophage
EMD SeronoApproved
Taltz
Eli LillyPhase 3
Retatrutide
Eli LillyPhase 3
GZR18
GGan & Lee Pharmaceuticals.
Phase 3
IBI362
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
HDM1002
HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3
RAY1225
GGuangdong Raynovent Biotech Co., Ltd
Phase 3
Glucophage
EMD SeronoPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
T2DM3 trials
Overweight2 trials
Exercise1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HS-20094. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details